

## STABILITY ANALYSIS OF A SEX-STRUCTURED MODEL OF CHLAMYDIA TRACHOMATIS AND PELVIC INFLAMMATORY DISEASE (PID)

**BOLARIN G.<sup>1</sup>, ODO C. E.<sup>2</sup>, OMATOLA, I. U.<sup>1</sup> & PHILLIP, M. A.<sup>2</sup>**

<sup>1</sup>Mathematics Department, FUT, Minna, Niger State

<sup>2</sup>Mathematics Department, Federal Polytechnic Bida, Niger State

**E-mail:** [g.bolarin@futminna.edu.ng](mailto:g.bolarin@futminna.edu.ng) **Phone No:** +234-818-714-1978

### Abstract

*In this work we developed and analyzed a mathematical model of chlamydia trachomatis and Pelvic Inflammatory Disease (PID): A sex-structured approach. The model is a first order Ordinary Differential Equations, in which the human population is divided into seven mutually- exclusive compartments namely; Susceptible male individuals ( $S_m$ ), Susceptible female individuals ( $S_f$ ), Infected male individuals ( $I_m$ ), Treated male individuals ( $T_m$ ), Infected female individuals without Pelvic Inflammatory Disease ( $I_f$ ), Treated female individuals ( $T_f$ ) and female individuals infected with Pelvic Inflammatory Disease ( $P_f$ ). The equilibrium states of the model were obtained and analyzed for stability. By using Bellman and Cooke's theorem, the endemic equilibrium state was found to be stable and the criteria for stability of the disease free equilibrium state were established.*

**Keywords:** Chlamydia Trachomatis, Pelvic Inflammatory Diseases (PID), equilibrium states, sex-structure

### Introduction

Pelvic inflammatory disease or pelvic inflammatory disorder (PID) is an infection of the upper part of the female reproductive system namely the uterus fallopian tubes, and ovaries, and inside of the pelvis (Campion *et al.*, 2015). Chlamydia trachomatis (chlamydia) has been found in approximately 30% of all PID cases (Low *et al.*, 2009) and is the most common bacterial sexually transmitted infection in many developed countries (WHO, 2001). Early detection and treatment of chlamydia through screening has been proposed as a strategy to prevent PID and subsequent reproductive tract morbidity in sexually active young women (Gottlieb *et al.*, 2010)

Globally about 106 million cases of chlamydia and 106 million cases of gonorrhoea occurred in 2008 (WHO, 2012). The number of cases of PID; however, is not clear. It is estimated to affect about 1.5 percent of young women yearly (Eschenbach, 2008). In the United States PID is estimated to affect about one million people yearly. Rates are highest with teenagers and first time mothers. PID causes over 100,000 women to become infertile in the US each year (CDC, 2010).

Symptoms in PID range from none to severe pains. If there are symptoms, then fever, cervical motion tenderness, lower abdominal pain, new or different discharge, painful intercourse, uterine tenderness, adnexal tenderness, or irregular menstruation may be noted (Mitchell & Prabhu, 2013).

The diagnosis is typically based on the presenting signs and symptoms. It is recommended that the disease be considered in all women of childbearing age who have lower abdominal pain. A definitive diagnosis of PID is made by finding pus involving the fallopian tubes during surgery. Ultrasound may also be useful in diagnosis (Mitchell *et al.*, 2013). Regular testing for sexually transmitted infections is encouraged for prevention (Smith *et al.*, 2007). Treatment is often started without confirmation of infection because of the serious


complications that may result from delayed treatment. Treatment depends on the infectious agent and generally involves the use of antibiotic therapy. If there is no improvement within two to three days, the patient is typically advised to seek further medical attention. Hospitalization sometimes becomes necessary if there are other complications. Treating sexual partners for possible STIs can help in treatment and prevention (CDC, 2014).

Mathematical modeling studies are a valuable tool for investigating hypothetical processes of chlamydia transmission and ascending infection. Amongst the few mathematical modeling studies with explicit descriptions of progression from chlamydia infection to PID, it has been proposed that PID develops in the first half of a chlamydia infection, in the second half, or can occur at any time during a chlamydia infection. Jacob and Catherine (2009), Dann *et al.*, (2013), and Herzog *et al.*, (2015) have all developed mathematical models of Chlamydia trachomatis and Pelvic inflammatory disease using heterogeneous population approach but none of them used a sex structured approach.

In this study, we will formulate a deterministic mathematical model for transmission dynamics of Chlamydia trachomatis and Pelvic inflammatory using a sex structured approach. The model to be developed considers a total population to be heterogeneous, non-constant and non-age structured. It should be clearly known that we are interested in investigating how susceptible male individuals can be infected via interaction with infected female individuals and vice-versa and then carry out the analysis.

**Model Formulation**

Mathematical model to study the dynamics of Chlamydia Trachomatis and Pelvic Inflammatory Disease using Sex-Structured Approach is presented in this section. The model divides the population into seven mutually-exclusive compartments namely; Susceptible male ( $S_m$ ), Infected male ( $I_m$ ), Treated male individuals ( $T_m$ ), Susceptible female ( $S_f$ ), Infected female ( $I_f$ ), Treated female individuals ( $T_f$ ) and Infected female with PID ( $P_f$ ). This can be shown as a flow diagram in which the circles represent the different compartments and the arrows represent the transition between the compartments.



**Fig. 1: A schematic description of the model**

**Basic Assumptions are:**

- (i) Susceptible male individuals can be infected via interaction with infected female individuals
- (ii) Susceptible female individuals can be infected via interaction with infected male individuals
- (iii) Infected female individuals can only develop PID if there is lack of treatment
- (iv) Homosexual interaction was not considered.

To describe this mathematically, we have the following differential equations;

$$\frac{dS_m}{dt} = (1-\theta)\Lambda + rT_m - (\lambda_f I_f + \mu)S_m \tag{1}$$

$$\frac{dS_f}{dt} = \theta\Lambda + eT_f + \omega P_f - (\lambda_m I_m + \mu)S_f \tag{2}$$

$$\frac{dI_m}{dt} = \lambda_f I_f S_m - (\mu + \gamma)I_m \tag{3}$$

$$\frac{dT_m}{dt} = \gamma I_m - (\mu + r)T_m \tag{4}$$

$$\frac{dI_f}{dt} = \lambda_m S_f I_m - (\mu + \rho + c)I_f \tag{5}$$

$$\frac{dT_f}{dt} = \rho I_f - (\mu + e)T_f \tag{6}$$

$$\frac{dP_f}{dt} = cI_f - (\mu + \omega)P_f \tag{7}$$

where

- $S_m$  Susceptible male
- $S_f$  Susceptible female
- $I_m$  Infected male
- $T_m$  Treated male
- $I_f$  Infected female
- $T_f$  Treated female
- $P_f$  Infected female with PID
- $\Lambda$  Constant recruitment rate
- $\mu$  Natural death rate
- $\gamma$  Recovery rate for infected male
- $\rho$  Recovery rate for infected female without PID
- $\omega$  The rate at which infected individuals with PID move to the susceptible class
- $e$  The rate which treated female move to susceptible class
- $c$  rate at which infected female develop PID

**Model Analysis**

**Positivity of Solution**

**Theorem 1:** Let the initial data be

$$\left\{ S_m(0) > 0, S_f(0) > 0, \left( I_m^{(0)}, T_m^{(0)}, I_f^{(0)}, T_f^{(0)}, P_f^{(0)} \geq 0 \right) \right\} \in D$$

Then the solution set  $\{S_m, S_f, I_m, T_m, I_f, T_f, P_f\}(t)$  of the system of equations (1) to (7) is positive for all  $t > 0$ .

**Proof:**

From the first equation (1)

$$\frac{dS_m}{dt} = (1 - \theta)\Lambda + rT_m - (\lambda_f I_f + \mu)S_m \geq -(\lambda_f I_f + \mu)S_m \tag{8}$$

$$\frac{dS_m}{dt} \geq -(\lambda_f I_f + \mu)S_m \tag{9}$$

Separating the variables we have

$$\frac{dS_m}{S_m} \geq -(\lambda_f I_f + \mu)dt \tag{10}$$

Integrating we have

$$\ln S_m \geq -(\lambda_f I_f + \mu)t + c \tag{11}$$

$$S_m(t) = e^{-(\lambda_f I_f + \mu)t + c} \tag{12}$$

$$S_m(t) \geq K e^{-(\lambda_f I_f + \mu)t} \tag{13}$$

Where  $k = e^c$

$$\text{Using the initial condition } t = 0 \Rightarrow S_m(0) \geq K \tag{14}$$

$$\text{Therefore, } S_m(t) \geq S_m(0)e^{-(\lambda_f I_f + \mu)t} \geq 0 \tag{15}$$

From equation (2)

$$\frac{dS_f}{dt} = \theta\Lambda + eT_f + \omega P_f - (\lambda_m I_m + \mu)S_f \geq -(\lambda_m I_m + \mu)S_f \tag{16}$$

$$\frac{dS_f}{dt} \geq -(\lambda_m I_m + \mu)S_f \tag{17}$$

Separating the variables

$$\frac{dS_f}{S_f} \geq -(\lambda_m I_m + \mu)dt \tag{18}$$

Integrating we have;

$$\ln S_f \geq -(\lambda_m I_m + \mu)t + c \tag{19}$$

$$S_f(t) = e^{-(\lambda_m I_m + \mu)t + c} \tag{20}$$

$$S_f(t) \geq k e^{-(\lambda_m I_m + \mu)t} \tag{21}$$

Using the initial condition  $t = 0 \Rightarrow S_f(0) \geq K$

$$\text{Therefore, } S_f(t) \geq S_f(0)e^{-(\lambda_m I_m + \mu)t} \geq 0 \tag{22}$$

Similarly, it can be verified that the rest of the equations are positive for all  $t > 0$  since  $e^\omega > 0$

For all  $\omega \in R$

**Equilibrium Points**

At equilibrium point  $\frac{dS_m}{dt} = \frac{dS_f}{dt} = \frac{I_m}{dt} = \frac{T_m}{dt} = \frac{I_f}{dt} = \frac{T_f}{dt} = \frac{dP_I}{dt} = 0$

Now, let  $S_m = x_1, S_f = x_2, I_m = x_3, T_m = x_4, I_f = x_5, T_f = x_6$  and  $P_f = x_7$

**Disease Free Equilibrium (DFE)**

The equilibrium state with no infection is called the disease free equilibrium state which is given below.

$$\begin{pmatrix} x_1 \\ x_2 \\ x_3 \\ x_4 \\ x_5 \\ x_6 \\ x_7 \end{pmatrix} = \begin{pmatrix} \frac{(1-\theta)\Lambda}{\mu} \\ \frac{\theta\Lambda}{\mu} \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{pmatrix}$$

**Stability Analysis**

**Stability Analysis of Disease Free Equilibrium State**

The Jacobian matrix at disease free equilibrium is:

$$J_{\left(\frac{(1-\theta)\Lambda}{\mu}, \frac{\theta\Lambda}{\mu}, 0, 0, 0, 0, 0\right)} = \begin{vmatrix} -\mu & 0 & 0 & r & -\lambda_f \frac{(1-\theta)\Lambda}{\mu} & 0 & 0 \\ 0 & -\mu & -\lambda_m \frac{\theta\Lambda}{\mu} & 0 & 0 & e & \omega \\ 0 & 0 & -(\mu+\gamma) & 0 & \lambda_f \frac{(1-\theta)\Lambda}{\mu} & 0 & 0 \\ 0 & 0 & \gamma & -(\mu+r) & 0 & 0 & 0 \\ 0 & 0 & \lambda_m \frac{\theta\Lambda}{\mu} & 0 & -(\mu+\rho+c) & 0 & 0 \\ 0 & 0 & 0 & 0 & \rho & -(\mu+e) & 0 \\ 0 & 0 & 0 & 0 & c & 0 & -(\mu+\omega) \end{vmatrix}$$

The characteristic equation

$$J(A-I\lambda) = \begin{vmatrix} -\mu-\lambda & 0 & 0 & r & -\lambda_f \frac{(1-\theta)\Lambda}{\mu} & 0 & 0 \\ 0 & -\mu-\lambda & -\lambda_m \frac{\theta\Lambda}{\mu} & 0 & 0 & e & \omega \\ 0 & 0 & -(\mu+\gamma)-\lambda & 0 & \lambda_f \frac{(1-\theta)\Lambda}{\mu} & 0 & 0 \\ 0 & 0 & \gamma & -(\mu+r)-\lambda & 0 & 0 & 0 \\ 0 & 0 & \lambda_m \frac{\theta\Lambda}{\mu} & 0 & -(\mu+\rho+c)-\lambda & 0 & 0 \\ 0 & 0 & 0 & 0 & \rho & -(\mu+e)-\lambda & 0 \\ 0 & 0 & 0 & 0 & c & 0 & -(\mu+\omega)-\lambda \end{vmatrix}$$

The determinant gives;

$$(-\mu-\lambda)(-\mu-\lambda)(-\mu+\gamma)-\lambda)(-\mu+r)-\lambda)(-\mu+\rho+c)-\lambda)(-\mu+e)-\lambda)(-\mu+\omega)-\lambda) = 0 \tag{23}$$

Either

$$(-\mu-\lambda) \text{ or } (-\mu-\lambda) \text{ or } (-\mu+\gamma)-\lambda \text{ or } (-\mu+r)-\lambda \text{ or } (-\mu+\rho+c)-\lambda \text{ or } (-\mu+e)-\lambda \text{ or } (-\mu+\omega)-\lambda = 0 \tag{24}$$

Therefore;

$$\lambda_1 = -\mu, \lambda_2 = -\mu, \lambda_3 = -(\mu+\gamma), \lambda_4 = -(\mu+r), \lambda_5 = -(\mu+\rho+c), \lambda_6 = -(\mu+e), \lambda_7 = -(\mu+\omega) \tag{25}$$

From (25)

$$\lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5, \lambda_6, \lambda_7 < 0$$

Hence, the DFE is stable

**Stability Analysis of Endemic Equilibrium State**

$$J(A-I\lambda) = \begin{vmatrix} -A_1-\lambda & 0 & 0 & r & -A_2 & 0 & 0 \\ 0 & -A_3-\lambda & -A_4 & 0 & 0 & e & \omega \\ A_5 & 0 & -A_6-\lambda & 0 & A_7 & 0 & 0 \\ 0 & 0 & \gamma & -A_8-\lambda & 0 & 0 & 0 \\ 0 & A_9 & A_{10} & 0 & -A_{11}-\lambda & 0 & 0 \\ 0 & 0 & 0 & 0 & \rho & -A_{12}-\lambda & 0 \\ 0 & 0 & 0 & 0 & c & 0 & -A_{13}-\lambda \end{vmatrix}$$

The determinant

$$(-A_1-\lambda)(-A_3-\lambda)(-A_6-\lambda)(-A_8-\lambda)(-A_{11}-\lambda)(-A_{12}-\lambda)(-A_{13}-\lambda) = 0 \tag{26}$$

Where

$$A_1 = \lambda_f I_f + \mu, A_2 = \lambda_f S_m, A_3 = \lambda_m I_m + \mu, A_4 = \lambda_m S_f, A_5 = \lambda_f I_f, A_6 = \mu + \gamma, A_7 = \lambda_f S_m$$

$$A_8 = (\mu + r), A_9 = \lambda_m I_m, A_{10} = \lambda_m S_f, A_{11} = \mu + \rho + c, A_{12} = \mu + e, A_{13} = \mu + \omega$$

Next we shall use the idea of Bellman and Cook (1963) to (26) to establish the stability or otherwise of the model.

**Lemma 1 (Bellman and Cooke (1963)):** Let  $H(Z) = P(z, e^z)$  where  $p(z, w)$  a polynomial with principal term.

Suppose  $H(iy), y \in R$ , is divided into its real and imaginary parts,

$$H(z) = F(y) + iG(y) \tag{27}$$

If all zeros of  $H(z)$  have negative real parts, then the zeros of  $F(y)$  and  $G(y)$  are real,

Simple and alternate and

$$G'(0)F(0) - G(0)F'(0) > 0 \text{ for all } y \in R. \tag{28}$$

Now let (26) take the form

$$H(\lambda) = (-A_1 - \lambda)(-A_3 - \lambda)(-A_6 - \lambda)(-A_8 - \lambda)(-A_{11} - \lambda)(-A_{12} - \lambda)(-A_{13} - \lambda) \tag{29}$$

Expanding and rearranging in ascending powers of  $\lambda$  we have

$$\begin{aligned} H(\lambda) = & -\lambda^7 + (A_1 + A_3 + A_6 + A_8 + A_{11} + A_{12} + A_{13})\lambda^6 \\ & + (-A_1 A_3 + (-A_1 - A_3)A_6 - (A_1 + A_3 + A_6)A_8 + \\ & (-A_1 - A_3 - A_6 - A_8)A_{11} - (A_1 + A_3 + A_6 + A_8 + A_{11})A_{12} \\ & + (-A_1 - A_3 - A_6 - A_8 - A_{11} - A_{12})A_{13})\lambda^5 + (A_1 A_3 A_6 \\ & - (-A_1 A_3 + (A_1 - A_3)A_6)A_8 + (A_1 A_3 - (-A_1 - A_3)A_6 + \\ & (A_1 + A_3 + A_6)A_8)A_{11} - (-A_1 A_3 + (-A_1 - A_3)A_6 - \\ & (A_1 + A_3 + A_6)A_8 + (-A_1 - A_3 - A_6 - A_8)A_{11})A_{12} \\ & + (A_1 A_3 - (-A_1 - A_3)A_6 + (A_1 + A_3 + A_6)A_8 - (-A_1 - \\ & A_3 - A_6 - A_8)A_{11} + (A_1 + A_3 + A_6 + A_8 + A_{11})A_{12}) \\ & A_{13})\lambda^4 + (-A_1 A_3 A_6 A_8 + (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 \\ & - A_3)A_6)A_8 + (A_1 A_3 - (-A_1 - A_3)A_6)A_8)A_{11} - (A_1 A_3 A_6 \\ & - (-A_1 A_3 + (-A_1 - A_3)A_6)A_8 + (A_1 A_3 - (-A_1 - A_3)A_6 + \\ & (A_1 + A_3 + A_6)A_8)A_{11})A_{12} + (-A_1 A_3 A_6 + (-A_1 A_3 + (A_1 - \\ & A_3)A_6)A_8 - (A_1 A_3 - (-A_1 - A_3)A_6 + (A_1 + A_3 + A_6)A_8)A_{11} + \\ & (-A_1 A_3 - (-A_1 - A_3)A_6 - (A_1 + A_3 + A_6)A_8) + (-A_1 - A_3 \\ & - A_6 - A_8)A_{11})A_{12})A_{13})\lambda^3 + (A_1 A_3 A_6 A_8 A_{11} - ((A_1 A_3 A_6)A_8) \\ & + (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 - A_3)A_6)A_8)A_{11})A_{12} \\ & + (A_1 A_3 A_6 A_8 - (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 - A_3)A_6)A_8)A_{11} \\ & + (A_1 A_3 A_6 (-A_1 A_3 - (-A_1 - A_3)A_6)A_8) + (A_1 A_3 - (-A_1 - A_3)A_6 \\ & + (A_1 + A_3 + A_6)A_8)A_{11})A_{12})A_{13})\lambda^2 + (-A_1 A_3 A_6 A_8 A_{11} \\ & + (-A_1 A_3 A_6 A_8 A_{11} + (-A_1 A_3 A_6 A_8 + (-A_1 A_3 A_6) \\ & (-A_1 A_3 + (-A_1 - A_3)A_6)A_8)A_{12})A_{13})\lambda + A_1 A_3 A_6 A_8 A_{11} A_{12} A_{13} \end{aligned} \tag{30}$$

Now set  $\lambda = i\omega$  in (30) and then apply the result of Bellman and Cook (1963)

Now set  $\lambda = i\omega$  in (30) and resolving into real and imaginary parts we have

$$H(i\omega) = F(\omega) + iG(\omega) \tag{31}$$

$$\begin{aligned}
 F(\omega) = & -(A_1 + A_3 + A_6 + A_8 + A_{11} + A_{12} + A_{13})(\omega)^6 \\
 & + (A_1 A_3 A_6 - (-A_1 A_3 + (A_1 - A_3) A_6) A_8 + (A_1 A_3 - \\
 & (-A_1 - A_3) A_6 + (A_1 + A_3 + A_6) A_8) A_{11} - (-A_1 A_3 + \\
 & (-A_1 - A_3) A_6 - (A_1 + A_3 + A_6) A_8 + (-A_1 - A_3 - A_6 \\
 & - A_8) A_{11}) A_{12} + (A_1 A_3 - (-A_1 - A_3) A_6 + (A_1 + A_3 \\
 & + A_6) A_8 - (-A_1 - A_3 - A_6 - A_8) A_{11} + (A_1 + A_3 + A_6 \\
 & + A_8 + A_{11}) A_{12}) A_{13})(\omega)^4 - (A_1 A_3 A_6 A_8 A_{11} - (-A_1 A_3 A_6) A_8) \\
 & + (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 - A_3) A_6) A_8) A_{11}) A_{12} + \\
 & (A_1 A_3 A_6 A_8 - (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 - A_3) A_6) A_8) A_{11} \\
 & + (A_1 A_3 A_6 (-A_1 A_3 - (-A_1 - A_3) A_6) A_8) + (A_1 A_3 - (-A_1 - A_3) A_6 \\
 & + (A_1 + A_3 + A_6) A_8) A_{11}) A_{12}) A_{13})(\omega)^2 + A_1 A_3 A_6 A_8 A_{11} A_{12} A_{13}
 \end{aligned} \tag{32}$$

$$\begin{aligned}
 G(\omega) = & \omega^7 + (-A_1 A_3 + (-A_1 - A_3) A_6 - (A_1 + A_3 + A_6) A_8 + \\
 & (-A_1 - A_3 - A_6 - A_8) A_{11} - (A_1 + A_3 + A_6 + A_8 + A_{11}) A_{12} \\
 & + (-A_1 - A_3 - A_6 - A_8 - A_{11} - A_{12}) A_{13})(\omega)^5 - \\
 & (-A_1 A_3 A_6 A_8 + (-A_1 A_3 A_6 + (-A_1 A_3 + (-A_1 \\
 & - A_3) A_6) A_8 + (A_1 A_3 - (-A_1 - A_3) A_6) A_8) A_{11} - (A_1 A_3 A_6 \\
 & - (-A_1 A_3 + (-A_1 - A_3) A_6) A_8 + (A_1 A_3 - (-A_1 - A_3) A_6 + \\
 & (A_1 + A_3 + A_6) A_8) A_{11}) A_{12} + (-A_1 A_3 A_6 + (-A_1 A_3 + (A_1 - \\
 & A_3) A_6) A_8 - (A_1 A_3 - (-A_1 - A_3) A_6 + (A_1 + A_3 + A_6) A_8) A_{11} + \\
 & (-A_1 A_3 - (-A_1 - A_3) A_6 - (A_1 + A_3 + A_6) A_8) + (-A_1 - A_3 \\
 & - A_6 - A_8) A_{11}) A_{12}) A_{13})(\omega)^3 + (-A_1 A_3 A_6 A_8 A_{11} \\
 & + (-A_1 A_3 A_6 A_8 A_{11} + (-A_1 A_3 A_6 A_8 + (-A_1 A_3 A_6) \\
 & (-A_1 A_3 + (-A_1 - A_3) A_6) A_8) A_{12}) A_{13})(\omega)
 \end{aligned} \tag{33}$$

Differentiating (32) and (33) with respect to  $w$  and putting  $w=0$

$$F'(0) = 0$$

$$\begin{aligned}
 G'(\omega) = & (-A_1 A_3 A_6 A_8 A_{11} + (-A_1 A_3 A_6 A_8 A_{11} + (-A_1 A_3 A_6 A_8 \\
 & + (-A_1 A_3 A_6) (-A_1 A_3 + (-A_1 - A_3) A_6) A_8) A_{12}) A_{13}
 \end{aligned} \tag{34}$$

Setting  $w=0$  (32) and (33)

$$F(0) = A_1 A_3 A_6 A_8 A_{11} A_{12} A_{13} \tag{35}$$

$$G(0) = 0 \tag{36}$$

Since  $F'(0) = 0, G(0) = 0, F(0) \neq 0$  and  $G' \neq 0$

Hence  $F(0)G'(0) - F'(0)G(0) > 0$

Therefore, the endemic equilibrium state is stable.

### Conclusion

In this study, we have formulated a deterministic mathematical model for transmission dynamics of Chlamydia trachomatis and Pelvic inflammatory using a sex structured approach. Based on the findings of this research, it could be seen that the Disease Free Equilibrium State (DFE) of the model is stable since all the eigen-values are less than zero and the analysis of the Endemic Equilibrium State (EE) indicated that it is stable since it satisfies the condition of Bellman and Cook  $F(0)G'(0) - F'(0)G(0) > 0$ . These results are in conformity with results of other authors.

### References

- Bellman, R., & Cooke, K. (1963). *Differential Equations*. London: Academic Press. Pp. 11-45
- Centers for Disease Control (2014). Retrieved February 21, 2017.
- Center for Disease Control (2010). Retrieved July 14, 2016.
- Campion, E. W., Brunham, R. C., Gottlieb, S. L., Paavonen, J. (2015). *Pelvic inflammatory disease*. *New England Journal of Medicine*, 372(21), 2039–2048.
- Dann, G. M, Masoumeh, B. A., Charisse, F. P., & Simpson, J. S. (2013). Mathematical model of chlamydial infection incorporating movement of chlamydial particles. 75, 2257–2270
- Eschenbach, D. (2008). Acute pelvic inflammatory disease. *Glob. libr. women's med.*  
[doi: 10.3843/GLOWM.10029](https://doi.org/10.3843/GLOWM.10029). *ISSN 1756-2228*.
- Gottlieb., S. L., Martin, D. H., Xu, F., Byrne, G. I., & Brunham, R. C. (2010). The natural history and immunobiology of Chlamydia trachomatis. *Genital Infection and Implications for Chlamydia Control. Journal of Infection Disease*, 201, S190–S204.
- Herzog., A, Christian L. A, Janneke., C. M, Pipp., O, Sally., K, Phillip., H., & Nicola, L. (2012). Timing of progression of *Chlamydia trachomatis* infection to pelvic inflammatory disease. 12(187),1471-2234.
- Jacob, A. D., & Catherine, H. (2009). Academic Journals. Full Length Research Paper Simplifying mathematical modelling to test intervention strategies for Chlamydia.
- Low, N., Bender, N., Nartey, L., Shang, A., Stephenson, J. M. (2009). Effectiveness of Chlamydia screening: Systematic review. *International Journal of Epidemiology*, 38, 435 – 448.
- Mitchell, C., & Prabhu, M. (2013). Pelvic inflammatory disease: Current concepts in pathogenesis, diagnosis and treatment. *Infectious disease clinics of North America*, 27(4), 793–809.
- Smith, K., Ness, R., & Wiesenfeld., H. (2007). Time from sexually transmitted infection acquisition to PID: Cost-effectiveness of alternative pelvic inflammatory disease treatment strategies. *Sex Transm Dis*, 10,358-366.

World Health Organization (2001). *Global prevalence and incidence of selected curable sexually transmitted infections: Overview and estimates*. Geneva: World Health Organization.

World Health Organization (2012). *Global incidence and prevalence of selected curable sexually transmitted infections - 2008 (PDF)*. [www.who.int](http://www.who.int). pp. 2, 19. Retrieved February 22, 2017.